Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical and Translational Radiation Oncology|
|State||Published - Sep 2020|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging